Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16560581 | 0.90 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL15627270 | 0.85 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL15611704 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL21180214 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL11310434 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL11310437 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL11310427 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL19308535 | 0.74 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL15627282 | 0.74 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PSEN1L3MBTL1 | |
| SCHEMBL24168852 | 0.71 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916564-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088111-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2D6, CYP2C19 | SLC6A2 683/4885SLC6A4 488/4885SLC6A3 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.